The potential of PADI4 to serve as a drug target in cancer was demonstrated by the finding that a small molecule inhibitor of PADI4 activated SESN2 and other p53 target genes leading to mTORC1 signaling pathway inhibition, perturbation of autophagy, and suppression of tumor cell growth (Wang et al., 2012). Here, TP53 is linked to cancer.